Dr. Nirav S. Patel, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of California, Geffen School of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 700
Licensed in California since 1994, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: University of California, Geffen School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license G79448 (first issued 1994; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
- Memorialcare Long Beach Medical Center Long Beach, CA
- Uci Health-Lakewood Lakewood, CA
Medical groups
- Oso Specialty Infusion Inc (9 clinicians)
- Southland Neurologic Institute A Medical Corporation (8 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 700
- Services billed
- 156,480
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 11,975 | 24 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 733 | 318 |
| Established patient office or other outpatient visit, 30-39 minutes | 376 | 241 |
| Established patient office or other outpatient visit, 40-54 minutes | 222 | 144 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 184 | 106 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 165 | 161 |
| Critical care, first 30-74 minutes | 130 | 112 |
| Measurement of brain wave activity (eeg), awake and drowsy | 80 | 79 |
| New patient office or other outpatient visit, 60-74 minutes | 52 | 52 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 36 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Los Alamitos, CA | 102 |
| Memantine Hcl Other prescribers in Los Alamitos, CA | 94 |
| Gabapentin Other prescribers in Los Alamitos, CA | 78 |
| Quetiapine Fumarate Other prescribers in Los Alamitos, CA | 44 |
| Tizanidine Hcl Other prescribers in Los Alamitos, CA | 40 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Los Alamitos, CA | 39 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Los Alamitos, CA | 39 |
| Baclofen Other prescribers in Los Alamitos, CA | 39 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Los Alamitos, CA | 37 |
| Pregabalin Other prescribers in Los Alamitos, CA | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 143 payments worth $30,579 in total to this clinician.
| Lundbeck LLC | $16,012 |
|---|---|
| Lilly USA, LLC | $11,655 |
| Novartis Pharmaceuticals Corporation | $515 |
| Amgen Inc. | $408 |
| AbbVie Inc. | $355 |
| Sk Life Science, Inc. | $249 |
| Amneal Pharmaceuticals LLC | $188 |
| Biogen, Inc. | $157 |
| Consulting Fee | $14,654 |
|---|---|
| Honoraria | $11,640 |
| Food and Beverage | $3,293 |
| Travel and Lodging | $849 |
| Education | $143 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Nov 24, 2025 | Consulting Fee KISUNLA · Neuroscience | $8,925 |
| Lundbeck LLC Feb 25, 2025 | Honoraria VYEPTI · NEUROLOGY | $3,395 |
| Lundbeck LLC May 28, 2025 | Honoraria VYEPTI · NEUROLOGY | $3,395 |
| Lundbeck LLC Sep 16, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $2,910 |
| Lundbeck LLC May 5, 2025 | Honoraria VYEPTI · NEUROLOGY | $2,910 |
| Lundbeck LLC Sep 3, 2025 | Honoraria VYEPTI · NEUROLOGY | $1,940 |
| Lilly USA, LLC Nov 24, 2025 | Consulting Fee KISUNLA · Neuroscience | $1,850 |
| Lundbeck LLC Sep 6, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $321 |
| Lilly USA, LLC Nov 14, 2025 | Travel and Lodging travel to SCOTTSDALE, CA · in-kind | $308 |
| Lilly USA, LLC Nov 14, 2025 | Travel and Lodging travel to SCOTTSDALE, CA · in-kind | $254 |
All 33 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Nov 24, 2025 | Consulting Fee KISUNLA · Neuroscience | $8,925 |
| Lilly USA, LLC Nov 24, 2025 | Consulting Fee KISUNLA · Neuroscience | $1,850 |
| Amgen Inc. Nov 20, 2025 | Education UPLIZNA · Inflammation/Rare Disease · in-kind | $28.63 |
| Lilly USA, LLC Nov 14, 2025 | Travel and Lodging travel to SCOTTSDALE, CA · in-kind | $308 |
| Lilly USA, LLC Nov 14, 2025 | Travel and Lodging travel to SCOTTSDALE, CA · in-kind | $254 |
| Lilly USA, LLC Nov 14, 2025 | Travel and Lodging travel to SCOTTSDALE, CA · in-kind | $182 |
| Amgen Inc. Oct 15, 2025 | Education UPLIZNA · Inflammation/Rare Disease · in-kind | $28.63 |
| Lundbeck LLC Sep 23, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $120 |
| Lundbeck LLC Sep 23, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $33.36 |
| Lundbeck LLC Sep 23, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $16.10 |
| Lundbeck LLC Sep 23, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $16.10 |
| Lundbeck LLC Sep 16, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $2,910 |
| Amgen Inc. Sep 16, 2025 | Education UPLIZNA · Inflammation/Rare Disease · in-kind | $28.63 |
| Lundbeck LLC Sep 6, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $321 |
| Lundbeck LLC Sep 6, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $37.59 |
| Lundbeck LLC Sep 6, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $35.00 |
| Lundbeck LLC Sep 6, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $25.00 |
| Lundbeck LLC Sep 6, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $23.44 |
| Lundbeck LLC Sep 5, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $193 |
| Lundbeck LLC Sep 5, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $43.72 |
| Lundbeck LLC Sep 3, 2025 | Honoraria VYEPTI · NEUROLOGY | $1,940 |
| Lundbeck LLC Sep 3, 2025 | Travel and Lodging VYEPTI · NEUROLOGY · travel to LONG BEACH, CA | $9.80 |
| Amgen Inc. Aug 27, 2025 | Education UPLIZNA · Inflammation/Rare Disease · in-kind | $28.63 |
| Lundbeck LLC Aug 19, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $45.00 |
| Lundbeck LLC Aug 12, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $60.00 |
| Amgen Inc. Jul 28, 2025 | Education UPLIZNA · Inflammation/Rare Disease · in-kind | $28.63 |
| Lundbeck LLC May 28, 2025 | Honoraria VYEPTI · NEUROLOGY | $3,395 |
| Lundbeck LLC May 5, 2025 | Honoraria VYEPTI · NEUROLOGY | $2,910 |
| Lundbeck LLC May 5, 2025 | Travel and Lodging VYEPTI · NEUROLOGY · travel to NEWPORT BEACH, CA | $36.40 |
| Lundbeck LLC May 5, 2025 | Travel and Lodging VYEPTI · NEUROLOGY · travel to NEWPORT BEACH, CA | $3.00 |
| Lundbeck LLC Feb 25, 2025 | Honoraria VYEPTI · NEUROLOGY | $3,395 |
| Lundbeck LLC Feb 25, 2025 | Travel and Lodging VYEPTI · NEUROLOGY · travel to PASADENA, CA | $49.00 |
| Lundbeck LLC Feb 25, 2025 | Travel and Lodging VYEPTI · NEUROLOGY · travel to PASADENA, CA | $7.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $327,309 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
Novartis Pharmaceuticals Corporation - A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK)
Janssen Research & Development, LLC - A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
H. Lundbeck A S · Completed · NCT06323928 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.